Gastroenterological Surgery, Division of Cancer Medicine, Department of Oncology, Graduate School of Medical Science, Kanazawa University, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan,
Clin Exp Med. 2013 Nov;13(4):289-95. doi: 10.1007/s10238-012-0202-9. Epub 2012 Jul 24.
Cytokeratin 18 (CK18) fragments are released into circulation during epithelial cell death. M30 (reflects caspase-cleaved CK18 fragment) and M65 (reflects total CK18 fragment) enzyme-linked immunosorbent assay (ELISA) detect circulating CK18 fragments released during caspase-dependent or total cell death, respectively; thus, CK18 has the potential of being a biomarker for epithelial cancers. In the present study, we investigated the serum levels of M30 and M65 in patients with gastric cancer, determined correlation of these levels with clinical features, and evaluated the usefulness of these enzymes as diagnostic and prognostic markers. We enrolled 54 gastric cancer patients and 12 healthy volunteers in this study. We measured the serum levels of M30 and M65 by quantitative ELISA. The levels of M30 and M65 in gastric cancer patients were significantly higher than those in healthy volunteers (P = 0.001, P < 0.001). The enzyme levels were elevated with the progress of gastric cancer. The sensitivity and specificity of M30 as a diagnostic marker were 67.5 and 90.9 %, respectively, and those of M65 were 70.1 and 90.9 %, respectively. The serum levels of M30 and M65 in patient with early gastric cancer were elevated in 38.1 and 66.7 %, respectively. Further, increased serum level of M65 is an independent indicator of poor prognosis (P = 0.036). The serum levels of M30 and M65 may be useful biomarkers for gastric cancer as diagnostic markers that can reflect the extent of cancer. Moreover, M65 levels can be used as a prognostic indicator.
细胞角蛋白 18 (CK18) 片段在上皮细胞死亡时释放到循环中。M30（反映半胱天冬酶切割 CK18 片段）和 M65（反映总 CK18 片段）酶联免疫吸附试验 (ELISA) 分别检测半胱天冬酶依赖性或总细胞死亡期间释放的循环 CK18 片段；因此，CK18 有可能成为上皮癌的生物标志物。本研究调查了胃癌患者血清中 M30 和 M65 的水平，确定了这些水平与临床特征的相关性，并评估了这些酶作为诊断和预后标志物的有用性。我们招募了 54 名胃癌患者和 12 名健康志愿者参加本研究。我们通过定量 ELISA 测量了 M30 和 M65 的血清水平。胃癌患者的 M30 和 M65 水平明显高于健康志愿者 (P=0.001，P<0.001)。随着胃癌的进展，酶水平升高。M30 作为诊断标志物的敏感性和特异性分别为 67.5%和 90.9%，M65 分别为 70.1%和 90.9%。早期胃癌患者的 M30 和 M65 血清水平分别升高 38.1%和 66.7%。此外，M65 血清水平升高是预后不良的独立指标 (P=0.036)。M30 和 M65 的血清水平可能是胃癌的有用生物标志物，作为反映癌症程度的诊断标志物。此外，M65 水平可用作预后指标。
